Hilde Windels
Président chez CELYAD ONCOLOGY SA
Profil
Ms. Hilde Windels is an Independent Director at PHAXIAM Therapeutics SA, a Chief Executive Officer & Director at Antelope Dx BV, a Chairman at Celyad Oncology SA, an Independent Non-Executive Director at MDxHealth SA, an Executive Chairman & Co-Chief Executive Officer at MyCartis NV and an Independent Director at Gimv NV.
She is on the Board of Directors at PHAXIAM Therapeutics SA, Antelope Dx BV, MDxHealth SA, Windels Hilde BV, Microphyt SA and Gimv NV.
Ms. Windels was previously employed as an Independent Director by Ablynx NV, an Independent Director by ERYTech Pharma SA, an Executive Director by Biocartis Group NV, a Chief Executive Officer by Biocartis SA, a Chief Financial Officer & Director by deVGen NV, a Manager by ING Bank NV, Amsterdam, succursale de Lancy/Genève, a Chief Financial Officer by SEPS Pharma NV, and a Chief Financial Officer by TiGenix NV.
She also served on the board at Vlaams Instituut voor Biotechnologie - Flanders Institute and FlandersBio vzw.
She received her graduate degree from Katholieke Universiteit Leuven.
Dernières actualités sur Hilde Windels
Postes actifs de Hilde Windels
Sociétés | Poste | Début |
---|---|---|
MDXHEALTH SA | Directeur/Membre du Conseil | 01/11/2017 |
CELYAD ONCOLOGY SA | Président | 23/06/2022 |
GIMV NV | Directeur/Membre du Conseil | - |
PHAXIAM THERAPEUTICS S.A. | Directeur/Membre du Conseil | 23/06/2023 |
Microphyt SA
![]() Microphyt SA BiotechnologyHealth Technology Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France. | Directeur/Membre du Conseil | - |
Antelope Dx BV
![]() Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Fondateur | 01/01/2019 |
Windels Hilde BV | Directeur/Membre du Conseil | 01/01/2001 |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Directeur Général | 01/01/2015 |
Anciens postes connus de Hilde Windels
Sociétés | Poste | Fin |
---|---|---|
Vlaams Instituut voor Biotechnologie - Flanders Institute
![]() Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | Directeur/Membre du Conseil | 01/06/2019 |
░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Hilde Windels
Katholieke Universiteit Leuven | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
BIOCARTIS GROUP NV | Health Technology |
MDXHEALTH SA | Health Technology |
CELYAD ONCOLOGY SA | Health Technology |
GIMV NV | Finance |
PHAXIAM THERAPEUTICS S.A. | Health Technology |
Entreprise privées | 12 |
---|---|
deVGen NV
![]() deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Health Technology |
SEPS Pharma NV
![]() SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Health Technology |
ING Bank NV, Amsterdam, succursale de Lancy/Genève
![]() ING Bank NV, Amsterdam, succursale de Lancy/Genève Regional BanksFinance ING Bank NV, Amsterdam, succursale de Lancy/Genève provides commercial banking services. Its banking products include saving and current accounts, credit cards, loans and investments. The firm offers vehicle insurance, home insurance, life insurance and retirement plans. The company was founded in 1871 and is headquartered in Brussels, Belgium. | Finance |
Biocartis SA
![]() Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Health Technology |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Commercial Services |
ERYTech Pharma SA
![]() ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Windels Hilde BV | |
Antelope Dx BV
![]() Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Technology Services |
Microphyt SA
![]() Microphyt SA BiotechnologyHealth Technology Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France. | Health Technology |
TiGenix NV
![]() TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |